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Abstract
In a multicentre study, inﬂuenza A/H1N1/09v 222G/N variants were more frequently detected in patients admitted to the intensive-care
unit for invasive mechanical ventilation or extracorporeal membrane oxygenation (10/23; 43.5%) than in patients hospitalized in other
units (2/27; 7.4%) and community patients (0/81; 0.0%) (p <0.01). A signiﬁcantly higher virus load (p 0.02) in the lower vs the upper
respiratory tract was observed. Predominance of 222G/N variants in the lower respiratory tract (40% of total virus population) vs the
upper respiratory tract (10%) was shown by clonal analysis of haemagglutinin sequences in paired nasal swab and bronchoalveolar lavage
samples. The time from illness onset to sampling was signiﬁcantly longer in patients with severe infection vs community patients
(p <0.001). It was concluded that the 222G/N variants showed increased virulence; mutant variants were probably selected in individual
patients; and the longer duration of illness might have favoured the emergence of adaptive mutations through multiple replication
cycles.
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Introduction
The 222G/N polymorphisms in the haemagglutinin (HA) gene
of inﬂuenza A/H1N1/09v pandemic virus have been associated
with cases of mild to severe illness from different countries
or geographical areas [1]. Mutant viruses have been reported
since April 2009, but no distinct phylogenetic clusterings or
consistent changes in virus antigenicity have been observed
[1]. Hence, it was suggested that the mutations occurred spo-
radically, as opposed to the sustained transmission of a vari-
ant virus. Recent studies from Norway, Hong Kong, Scotland
and Spain have shown a higher prevalence of 222G/N in
patients with severe illness [2–5], whereas the polymorphism
222E was not associated with increased virulence [2]. In addi-
tion, the low prevalence of the 222G variants in fatal cases
(26/364, 7.1%) and the limited information about potential
underlying medical conditions in these cases make it difﬁcult
to determine the clinical relevance of this polymorphism [1].
Patients in these studies were stratiﬁed on the basis of broad
deﬁnitions of the severity of the inﬂuenza-like illness (ILI) in
the absence of precise clinical parameters. The clinical impact
of these amino acid polymorphisms is still debated [2].
In this report, the association of polymorphisms at codon
222 of the virus HA with the severity of the clinical presen-
tation was investigated in a multicentre study in three groups
of patients with inﬂuenza A/H1N1/09v infection.
Materials and Methods
Two reference centres for surveillance of pandemic inﬂuenza
A infection in Pavia and Milan as well as two reference inten-
sive care units (ICU) for advanced critical care including
extracorporeal membrane oxygenation (ECMO) procedure,
in Pavia and Palermo, participated in the study. Following the
criteria indicated by Zarychanski et al. [6], patients were
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stratiﬁed as follows: (i) group A (severe ILI) consisted of 23
sequential patients (males 13/23, 56.5%, median age 35 years,
range 11–60 years) with acute respiratory distress syndrome
characterized by bilateral alveolar inﬁltrates on chest radiog-
raphy and rapidly progressive hypoxaemia [7], admitted to
ICUs for invasive mechanical ventilation or ECMO proce-
dures; (ii) group B (moderate ILI) consisted of a comparable
number (n = 27) of sequential patients (males 17/27, 62.6%;
median age 43 years, range 1–85 years) with lower respira-
tory tract infection, (positive chest radiography and/or
reduced pO2 blood saturation, pO2 < 90%), requiring admis-
sion to units other than ICUs for antiviral and/or oxygen
supplementation by non-invasive assisted ventilation proce-
dures; (iii) group C comprised a three-fold greater number
of patients (n = 81), consisting of patients (males 43/81,
53.0%; median age 21 years, range 3–77 years) with mild ILI
(control group). The 81 controls were randomly selected
among patients diagnosed with inﬂuenza A/H1N1/09v
infection at the reference centres in Pavia and Milan during
the national surveillance programme in the period April–
November 2009, and consisted of patients with community-
acquired self-resolving ILI, not requiring hospitalization,
administration of antiviral drugs or oxygen supplementation
(mild ILI).
Clinical decisions were based upon prospective diagnosis
of inﬂuenza A/H1N1/09v performed by a real-time RT-PCR
(Centers for Disease Control, Atlanta, GA, USA), whereas
patient stratiﬁcation, virus load determination and HA gene
analysis were performed retrospectively. In detail, virus load
in nasal swab and bronchoalveolar lavage (BAL) samples was
obtained by interpolation of real-time RT-PCR threshold val-
ues from clinical samples on a standard curve obtained by
parallel ampliﬁcation of quantitative standards consisting of
serial dilutions of a recombinant plasmid construct carrying
the HA target sequence. The presence of amino acid poly-
morphisms at codon 222 of the HA gene of inﬂuenza A/
H1N1/09v strains was determined by RT-PCR ampliﬁcation
of the HA gene directly from clinical specimens. An amplicon
of 800 base pairs was obtained using H1N1v-speciﬁc primers
(HA-swF2, GCA AGC TCA TGG TCC TAC ATT GTG GA;
HA-swR3, CCC TTC AAT GAA ACC GGC AAT GG). The
RT-PCR were carried out using the Ag-Path-ID one-step RT-
PCR kit (Applied Biosystems, Foster City, CA, USA) in a
GeneAmp PCR System 9700 thermal cycler (Applied Bio-
systems) using the following thermal proﬁles: one cycle at
50C for 15 min and 95C for 10 min, followed by 50 cycles
at 95C for 60 s, 60C for 60 s and 72C for 70 s, with a
ﬁnal elongation of 7 min at 72C. Sequencing of the HA
amplicon was performed with internal primers (HA-swF3,
TAA CGG CAG CAT GTC CTC ATG CTG GA; HA-swR2,
GAG GCT GGT GTT TAT AGC ACC CTT GG) using the
BigDye Terminator Cycle-Sequencing Ready Reaction and
ABI Prism 3100 DNA sequencer (Applied Biosystems).
Sequences were then assembled and aligned using SEQUEN-
CHER (version 4.7; Gene Code Corp., Ann Arbor, MI, USA)
and BIOEDIT software.
The relative proportion of wild-type and mutant viruses in
the upper vs lower respiratory tract was analysed by clonal
analysis of HA sequences from paired nasal swab and BAL
specimens. Brieﬂy, HA amplicons were cloned into the
pCR2.1 plasmid vector (TA Cloning kit; Invitrogen, Gronin-
gen, the Netherlands) and ten plasmid clones from each
specimen were individually sequenced following in principle a
previously reported procedure [8].
Comparison of viral load was performed with the Mann–
Whitney rank-sum test for continuous variables and the chi-
square test or Fisher’s exact test for categorical variables
was used for analysis of 222G/N prevalence.
Results
Virus strains with the 222G/N polymorphisms were more
frequently detected in patients of group A (10/23, 43.5%)
with respect to both groups B (2/27, 7.4%) and C (0/81,
0.0%) (p <0.01). A similar trend was observed also between
groups B and C (p 0.06).
The median virus load in nasal swabs of patients in groups
A (5.7 · 104, range 1.0 · 100 to 6.9 · 106) and B (6.5 · 104,
range 1.0 · 100 to 1.7 · 108) was signiﬁcantly lower than
that detected among patients in the control group
(3.1 · 106, range 1.0 · 100 to 9.0 · 108) (p 0.01).
The time span from illness onset to sampling of patients
was signiﬁcantly longer in patients of groups A (4.5 days,
range 1–6) and B (5.5 days, range 1–10) with respect to
group C (1 day, range 1–6) (p <0.001). On the other hand,
the time span from illness onset to sampling of patients of
groups A and B with the 222G/N variants (6 days, range 4–
7) compared with the patients of groups A and B with the
222D/E variants (3 days, range 1–10) was not signiﬁcantly dif-
ferent (p >0.05).
In nine patients (seven in group A and two in group B)
paired nasal swab and BAL samples were available. In these
patients, virus load was signiﬁcantly higher in the lower
respiratory tract (median 2.4 · 105 RNA copies/mL) than in
the upper respiratory tract (median 2.8 · 103 RNA copies/
mL) (p 0.01) (Fig. 1a).
In two of these patients (pt#5 and #6), the HA sequence
from the nasal swab could not be obtained because of low
virus load (< 10 virus RNA copies/mL). In four patients
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(44.4%), no 222G/N variants were detected in either nasal
swab or BAL, but the remaining ﬁve patients (55.5%) showed
the presence of 222G/N variants. In three out of four
(75.0%) patients with 222G/N variants and available HA
sequence in both nasal swab and BAL, the mutant viruses
were detected only in the lower respiratory tract, whereas
in a single patient (pt#2) a 222N variant was detected both
in nasal swab and BAL samples (Fig. 1b). In these four
patients (pt#2, #3, #8 and #9), the relative proportion of
wild-type and mutant viruses in the upper vs lower respira-
tory tract was investigated by clonal analysis of HA
sequences. For comparison, ten HA plasmid clones were also
obtained from the nasal swab and BAL samples of pt#4, who
did not show the presence of 222G/N variants in either
specimen (Fig. 1b). The 222G/N variants were detected at
clonal level in all patients. However, a signiﬁcantly (p <0.001)
higher proportion of mutant variants was observed in the
lower (median 40% clones, range 20–90%) than the upper
(median 10% clones, range 0–60%) respiratory tract. Inter-
estingly, in pt#2, who showed by direct sequencing 222G/N
variants in both nasal swab and BAL, a comparable number
of mutant variant specimens was observed by clonal analysis
in both specimens (six of ten clones, 60% and ﬁve of ten
clones, 50%, respectively). Although direct sequencing of HA
amplicons from nasal swabs of pt#3, #8 and #9 did not
detect mutant viruses, a minor proportion of 222G/N vari-
ants was shown in pt#3 and #9 by clonal analysis (one of ten
clones, 10%). Similarly, a minor proportion of 222G/N vari-
ants not detected by direct sequencing was shown in nasal
swab (one of ten, 10%) and BAL (two of ten, 20%) clones of
pt#4.
Discussion
Using a stringent clinical deﬁnition of the severity of ILI in a
multicentre prospective study, the association between the
emergence of inﬂuenza A/H1N1/09v 222G/N virus variants
and increased virulence was documented. Frequency of
222G/N variants in patients with severe ILI was strikingly
higher than that in patients with moderate or mild ILI. Simi-
larly, patients with moderate ILI more frequently harboured
mutant viruses. In addition, it was shown that mutant virus
variants segregated preferentially in the lower respiratory
tract, where increased virus replication and higher virus load
were also shown. Although paired upper and lower respira-
tory tract specimens at speciﬁed intervals from all patients
with lower respiratory tract disease could not be systemati-
cally obtained in this observational study, the ﬁndings here
reported support the hypothesized higher afﬁnity of the
222G/N variants for the avian-like a2,3-sialic acid receptors
present in the low respiratory tract as opposed to the higher
afﬁnity of the 222D/E variants for the human-like a2,6-sialic
acid receptors exclusively present in the upper respiratory
tract [9,10]. The observed predominance of 222G/N strains
in the lower respiratory tract further strengthens the hypoth-
esis of their ﬁtness in this biological environment. In addition,
the frequent detection of mixtures of different virus variants
supports the hypothesized sporadic selection of the 222G/N
variants in individual patients, as opposed to their circulation
in the population. This hypothesis is also supported by the
longer duration of illness in patients of groups A and B with
respect to group C, which might have favoured the emer-
gence of adaptive mutations in the HA through multiple repli-
cation cycles. Indeed, a potential epidemic cluster of 222G/N
virus variants in our patients was excluded on the basis of dif-
ferential nucleotide signatures along the entire HA gene as
well as on the unlikeliness of the simultaneous occurrence of
such an event in three centres located in northern and south-
ern Italy. On the other hand, the patient clonal analysis
showed a small proportion of 222G/N variants not detected
by direct sequencing, suggesting that the prevalence of such
FIG. 1. (a) Inﬂuenza A/H1N1/09v load in paired nasal swabs (NS)
and bronchoalveolar lavage (BAL) samples of seven patients with
severe inﬂuenza-like illness (ILI) and two patients with moderate ILI.
(b) Inﬂuenza A/H1N1/09v amino acid polymorphisms (predominance)
in paired NS and BAL samples of seven patients with severe ILI and
two patients with moderate ILI.
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variants in patients with severe or moderate ILI might have
been underestimated by the routine sequencing assay.
The infection of the lower respiratory tract was more fre-
quently associated with higher virus load with respect to the
upper respiratory tract, concomitantly with severe tissue
damage and highly impaired O2 exchange. The prolonged time
of illness in patients of groups A and B with respect to
patients of group C appears to be associated with the localiza-
tion of infection from the upper to the lower respiratory tract
and, ﬁnally with selection of mutant virus variants that ﬁt bet-
ter into the new environment. In contrast, a reduced ability of
mutated virus variants to spread through inter-human infec-
tion of the upper respiratory tract might have accounted for
the reduced circulation of 222G/N variants and the mild clini-
cal impact of the 2009 inﬂuenza A pandemic [11].
In conclusion, the 222G/N polymorphisms in the inﬂuenza
A/H1N1/09v HA are associated with signiﬁcant virulence and
the virulent variants appear to have arisen sporadically,
remaining restricted to the lower respiratory tract of
patients with highly impaired respiratory function. The
reported low prevalence of 222G/N variants observed during
the 2009 pandemic suggests a low circulation of the virulent
virus variants, but it also reveals a potential diagnosis bias
because of the widespread use of the upper respiratory tract
secretions as a specimen of choice also in patients with
severe lung infection. Finally, the potential increase in circula-
tion of such variants in the next seasonal epidemics or a re-
assortment of these viruses with other human or animal
inﬂuenza A strains poses serious clinical and public health
concerns.
Inﬂuenza A/H1N1/09v variants with 222G/N polymor-
phisms showed increased clinical virulence, and detection of
such mutants in the next epidemics is mandatory for better
management of ILI in individual patients as well as for surveil-
lance purposes.
Acknowledgements
We thank all the technical staff of the Virology Unit, Laurene
Kelly for revision of the English, and Daniela Sartori for editing.
Transparency Declaration
This work was partially supported by the Ministero della
Salute, Ricerca Corrente (grant 80622) and Ricerca Finalizz-
ata (convenzione n. 53). The authors declare no conﬂicts of
interest.
References
1. World Health Organization. Preliminary review of D222G amino acid
substitution in the haemagglutinin of pandemic inﬂuenza A(H1N1)
2009 viruses. Wkly Epidemiol Rec 2010; 85: 21–22.
2. Kilander A, Rykkvin R, Dudman SG, Hungnes O. Observed associa-
tion between the HA1 mutation D222G in the 2009 pandemic inﬂu-
enza A(H1N1) virus and severe clinical outcome, Norway 2009–
2010. Euro Surveill 2010; 15: 19498.
3. Mak GC, Au KW, Tai LS et al. Association of D222G substitution in
haemagglutinin of 2009 pandemic inﬂuenza A (H1N1) with severe
disease. Euro Surveill 2010; 15: 19534.
4. Miller RS, MacLean AR, Gunson RN, Carman WF. Occurrence of
hemagglutinin mutation D222G in pandemic inﬂuenza A(H1N1)
infected patients in the West of Scotland, United Kingdom, 2009–10.
Euro Surveill 2010; 15: 19546.
5. Anton A, Marcos MA, Martinez MJ et al. D225G mutation in the
hemagglutinin protein found in 3 severe cases of 2009 pandemic
inﬂuenza A (H1N1) in Spain. Diagn Microbiol Infect Dis 2010; 67:
207–208.
6. Zarychanski R, Stuart TL, Kumar A et al. Correlates of severe disease
in patients with 2009 pandemic inﬂuenza (H1N1) virus infection.
CMAJ 2010; 182: 257–264.
7. Bernard GR, Artigas A, Brigham KL et al. The American–European
Consensus Conference on ARDS. Deﬁnitions, mechanism, relevant
outcomes, and clinical trial coordination. Am J Respir Crit Care Med
1994; 149: 818–824.
8. Paolucci S, Baldanti F, Campanini G et al. Analysis of HIV drug-resis-
tant quasispecies in plasma, peripheral blood mononuclear cells and
viral isolates from treatment-naive and HAART patients. J Med Virol
2001; 65: 207–217.
9. Shen J, Ma J, Wang Q. Evolutionary trends of A(H1N1) inﬂuenza
virus hemagglutinin since 1918. PLoS ONE 2009; 4: e7789.
10. Newhouse EI, Xu D, Markwick PR et al. Mechanism of glycan recep-
tor recognition and speciﬁcity switch for avian, swine, and human
adapted inﬂuenza virus hemagglutinins: a molecular dynamics perspec-
tive. J Am Chem Soc 2009; 131: 17430–17442.
11. Puzelli S, Facchini M, Spagnolo D et al. Transmission of hemagglutinin
D222G mutant strain of pandemic (H1N1) 2009 virus. Emerg Infect
Dis 2010; 16: 863–865.
CMI Baldanti et al. Severe ILI due to 222G/N Flu AH1N1v variants 1169
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1166–1169
